Petition seeks Nawaz Sharif's live speeches be banned

Agencies
May 16, 2018

Islamabad, May 16: The Islamabad High Court (IHC) on Wednesday admitted a petition seeking a ban on live speeches of former prime minister Nawaz Sharif.

The petition also sought to commence a criminal proceeding against Sharif for his statement on the 2008 Mumbai terror attacks.

Advocate Babar Awan, a leader of the Pakistan Tehreek-i-Insaf (PTI) has filed the petition on the behest of a local lawyer.

According to the report, the petition stated that Sharif on May 3, during his appearance before the accountability court, had threatened to reveal some national secrets.

The petition requested the court to direct the Federal Investigation Agency (FIA) to initiate legal proceedings against Sharif.

Justice Aamer Farooq sought reply from the director general of the FIA, chairmen Pakistan Electronic Media Regulatory Authority (Pemra) and Pakistan Telecommunication Authority (PTA) with respect to the filed petition.

He questioned if the court could impose a ban on someone delivering speeches.

Last week, during an interview with the Dawn, Sharif had stated that "Militant organisations are active. Call them non-state actors, should we allow them to cross the border and kill 150 people in Mumbai? Explain it to me. Why can't we complete the trial?"

"We have isolated ourselves. Despite giving sacrifices, our narrative is not being accepted. Afghanistan's narrative is being accepted, but ours is not. We must look into it," he added.

His remarks were immediately picked up by Indian media, which termed the former prime minister's statement as a confession of Pakistan's role in the Mumbai attacks that left 166 people dead.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 4,2020

Tokyo, Mar 4: Takeda Pharmaceutical Co said on Wednesday it was developing a drug to treat COVID-19, the flu-like illness that has struck more than 90,000 people worldwide and killed over 3,000.

The Japanese drugmaker is working on a plasma-derived therapy to treat high-risk individuals infected with the new coronavirus and will share its plans with members of the U.S. Congress on Wednesday, it said in a statement.

Takeda is also studying whether its currently marketed and pipeline products may be effective treatments for infected patients.

"We will do all that we can to address the novel coronavirus threat...(and) are hopeful that we can expand the treatment options," Rajeev Venkayya, president of Takeda's vaccine business, said in the statement.

Takeda said it was in talks with various health and regulatory agencies and healthcare partners in the United States, Asia and Europe to move forward its research into the drug.

Its research requires access to the blood of people who have recovered from the respiratory disease or who have been vaccinated, once a vaccine is developed, Takeda said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
March 25,2020

Beijing:  Around 5,000 people have signed up for the phase I clinical trial of recombinant novel coronavirus vaccine in Chinese city Wuhan where the virus first emerged late last year.

The recruitment for participants ended this week with nearly 5,000 volunteers signing up for the trial, state-run Beijing News reported on Wednesday.

A single-centre, open and dose-escalation phase I clinical trial for recombinant novel coronavirus vaccine (adenoviral vector) will be tested in healthy adults aged between 18 and 60 years, according to the ChiCTR (China Clinical Trial Register).

The trial, led by experts from the Academy of Military Medical Sciences, gained its approval on March 16 and the research is expected to last half a year.

Requiring at least 108 participants, the trial will be conducted in Wuhan, capital of Hubei province, the region worst-affected by the virus in the country, state-run China Daily reported.

Participants will experience 14-day quarantine restrictions after being vaccinated and their health condition will be recorded every day.

Chinese scientists are hastening the development of COVID-19 vaccines through five approaches --- inactivated vaccines, genetic engineering subunit vaccines, adenovirus vector vaccines, nucleic acid vaccines and vaccines using attenuated influenza virus as vectors.

So far, most teams are expected to complete preclinical research in April and some are moving forward faster, Wang Junzhi, an academician with the Chinese Academy of Engineering said.

Wang noted that research and development of COVID-19 vaccines in China is not slower than foreign counterparts and has been carried out in a scientific, standardised and orderly way.

China has stepped up the process to finalise vaccines to counter COVID-19 after Kaiser Permanente research facility in Seattle and Washington stole the march and began human trials.

China lifted tough restrictions on the Hubei province on Wednesday after a months-long lockdown as the country reported no new domestic cases.

But there were another 47 imported infections from overseas, the National Health Commission said. In total, 474 imported infections have been diagnosed in China -- mostly Chinese nationals returning home.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
June 1,2020

New Delhi, Jun 1: Actor Kendrick Sampson, who stars in HBO series Insecure, was struck by rubber bullets as Los Angeles police officers tried to disperse a crowd protesting George Floyd”s death in Minneapolis.

Floyd, a black man, died last Monday in Minneapolis, Minnesota after a white police officer pressed his knee on his neck for more than eight minutes. The officer was arrested on Friday and charged with third-degree murder.

The actor went live via Instagram on Saturday to show his view of events, but he could be also be seen on a CNN broadcast simultaneously, with viewers watching him get hit by a police baton on TV.

Sampson posted several videos on his page of a large demonstration at Pan Pacific Park near the city”s Fairfax District, where violent clashes took place throughout the day outside the Grove shopping center.

In one video, LAPD officers can be seen firing rubber bullets to try and regain control at the park.

“They shot me four times already. I already got hurt and I got hit with a baton,” Sampson said in the video on Instagram.

Another clip showed him moving away from the police, as he appeared to be hit by an officer”s baton.

“Y”all ain”t see no police f*****g up white folks when they took guns to the statehouse,” he said, referring to an incident in Michigan over coronavirus restrictions, not in California. “Y”all didn”t see police attacking white folks, beating em up with batons, shooting them with rubber bullets when they brought guns to f*****g state houses. We came up here with no weapons, with masks.… And we”re the ones who are not peaceful,” Sampson alleged.

Protests turned violent over Floyd”s death and other police killings of black people spread Saturday in dozens of US cities, with police cars set ablaze, reports of injuries mounting on all sides, shops and showrooms vandalised amid the lockdown.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.